Abstract Undifferentiated connective tissue disease (UCTD) is a unique clinical entity, a potential forerunner of wellestablished systemic autoimmune/rheumatic diseases. UCTD is characterized by the presence of various clinical symptoms, as well as a diverse repertoire of autoantibodies, resembling systemic autoimmune diseases. Since approximately one third of these patients consequently transform into a full-blown systemic autoimmune/rheumatic disease, it is of major importance to assess pathogenic factors leading to this progression. In view of the fact that the serological and clinical picture of UCTD and systemic autoimmune diseases are very similar, it is assumed that analogous pathogenic factors perpetuate both disease entities. In systemic autoimmune conditions, a quantitative and qualitative impairment of regulatory T cells has been shown previously, and in parallel, a relative dominance of pro-inflammatory Th17 cells has been introduced. Moreover, the imbalance between regulatory and Th17 cells plays a pivotal role in the initiation and propagation of UCTD. Additionally, we depict a cytokine imbalance, which give raise to a biased T cell homeostasis from the UCTD phase throughout the fully developed systemic autoimmune disease stage. The levels of interleukin (IL)-6, IL-12, IL-17, IL-23, and interferon (IFN)-γ were pathologically increased with a parallel reduction of IL-10. We believe that the assessment of Th17/Treg cell ratio, as well as the simultaneous quantitation of cytokines may give a useful diagnostic tool at the early UCTD stage to identify patients with a higher chance of consecutive disease progression toward serious systemic autoimmune diseases. Moreover, the early targeted immunomodulating therapy in these patients may decelerate, or even stop this progression, before the development of serious autoimmune conditions with organ damage.
Introduction

Undifferentiated Connective Tissue Disease (UCTD)
Undifferentiated connective tissue disease (UCTD) is a unique clinical entity, a potential forerunner of a subsequentially developing full-blown systemic autoimmune/rheumatic disease. UCTD is characterized by the presence of various clinical symptoms, resembling rheumatic diseases, as well as a diverse repertoire of autoantibodies. The most common clinical symptoms of the disease include Raynaud's phenomenon, fever, arthritis, serositis (pleuritis, pericarditis), sicca symptoms, skin involvement (photosensitivity, rash), central and peripheral nervous system symptoms, vasculitis, pulmonary involvement, myositis, and accelerated atherosclerosis [1] . The serological abnormalities can include the presence of the following autoantibodies: anti-nuclear (ANA), antidsDNA, -Sm, -RNP, -SSA, -SSB, -Scl-70, -centromere, -Jo1, or -PM-Scl, amongst others [1] . However, this clinicalserologic constellation does not fulfill the diagnostic criteria of any well-defined rheumatic, systemic autoimmune diseases, amongst others rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome, idiopathic inflammatory myopathies (IIMs), mixed connective tissue disease (MCTD), or systemic sclerosis (SSc) [2] [3] [4] [5] [6] . The most important clinical feature of UCTD is that over one third of these patients consequently transform into a full-blown systemic autoimmune/rheumatic disease [1] . In our previous study, we followed up 665 UCTD patients for 5 years and showed that 34.5 % of these patients developed a well-defined systemic autoimmune disease, with the following end-disease progressions: 38 % RA, 20 % Sjögren's syndrome, 12 % SLE, 11 % MCTD, 10 systemic vasculitis, 8 % progressive SSc, and 1 % IIMs [1] . The highest probability of evolution to a defined systemic autoimmune/rheumatic disease was during the first 2 years after onset.
The Pathogenesis of UCTD As we have depicted previously, UCTD both in clinical symptoms and serologically resembles systemic autoimmune diseases, which raises the possibility that similar factors are involved in the pathogenesis of these clinical entities. Moreover, since UCTD can be the forerunner of subsequentially developing rheumatic diseases, it is plausible that the escalation and intricate interplay of certain pathogenic factors in the UCTD stage lead to disease progression. UCTD and fully developed systemic autoimmune diseases are typically multietiological entities, where genetic, environmental abnormalities along with derailed immunoregulatory processes contribute to the development of the disease. In the healthy immune system, various tolerance mechanisms, such as activation-induced cell death, the functional inertness, denoted as anergy, or clonal ignorance play a crucial role to prevent the activation of self-reactive lymphocytes [7] . In autoimmune conditions with faulty tolerance mechanisms, self-reactive lymphocytes may not be subjected to peripheral deletion, or anergy raising the possibility of the survival and activation of autoreactive T and B cells upon autoantigen encounter [8] [9] [10] . However, there is a fine line between autoimmune processes, which also appear in healthy individuals and manifested autoimmune diseases. In autoimmune diseases, one or several tolerance mechanisms permanently fail due to the constellation of various environmental factors, specific HLA and non-HLA genes and derailed immunoregulatory processes, leading to the persistence of selfreactive T and B cell clones and ultimately organ damage [10, 11] . Since similar clinical and pathogenic features can be found between UCTD and developed systemic autoimmune diseases, we hypothesized that immunoregulatory abnormalities and/or the imbalance of immunoregulatory and inflammatory processes at the UCTD stage could lead to the progression toward systemic autoimmune diseases. [12] . It is reasonable to speculate that when regulatory T cells are reduced in numbers or functionally impaired, pro-inflammatory immune responses are evoked, and upon susceptible genetic background, autoimmune processes can occur, leading to the spontaneous development of various autoimmune diseases. In line with this hypothesis, previous studies conducted on patients with systemic autoimmune and rheumatic disease described that the selective decrease in the number of Tregs or, alternatively, a diminished suppressor function of Tregs are characteristic to these diseases (e.g., SLE, MCTD, Sjögren's syndrome or RA [13] [14] [15] [16] [17] . These data indicate that in patients with established autoimmune conditions, a well-characterized quantitative and/ or qualitative impairment of the regulatory T cell pool exists.
As a natural follow-up to these findings, we previously investigated the regulatory T cell pool of patients with UCTD [18] . In these patients, the assessment of Treg cells showed that the percentage and absolute number of CD4 + CD25 bright FoxP3+, natural Tregs were diminished in UCTD patients compared with healthy controls, while the number of CD4+IL-10+, inducible Tregs was increased [18] . This progressive divergent shift in natural and induced T regulatory cells clearly predicted the transition from the undifferentiated connective tissue disease to a well-established systemic autoimmune disease [18] . Interestingly, we and others have described that in patients with active systemic autoimmune diseases, such as SLE or MCTD, the frequency of CD4+ CD25 bright FoxP3+ Tregs was found to be decreased compared to healthy individuals or interestingly in patients with an inactive disease state [13, 15, 19] . The other major regulatory T cell subset, denoted as IL-10 producing type-1 regulatory T cells (CD4+IL-10+, Tr1) has been implicated in various autoimmune diseases [20] . IL-10 is a multifunctional cytokine that can suppress the interferon (IFN)-γ production of Th1 cells and regulate growth and/or differentiation of various T cell types, B cells, or NK cells [21, 22] . In relation to this, we discovered a significant increase in Tr1s when UCTD patients were compared with healthy controls, and we found further increase in patients who progressed into definitive systemic autoimmune diseases. This could be interpreted as a compensatory mechanism to downmodulate the effects of the observed IFN-γ overproduction [18] .
Th17 Cells and the Th17/Treg Ratio in Systemic Autoimmune Diseases and UCTD On the pro-inflammatory side, T cells have the ability to differentiate into IL-17-producing T helper cells, denoted as Th17 cells, and this differentiation is independent of Th1 or Th2 cell development [23, 24] . Th17 cells recruit neutrophils and macrophages to the site of inflammation; therefore, they are crucial in pro-inflammatory immunological processes, in the combat against pathogens, mostly against extracellular pathogens [24] . Dysregulated synthesis and increased levels of Th17 cells have been associated with numerous inflammatory conditions, as well as with autoimmune diseases. Amongst others, increased levels of IL-17 has been shown in the sera, synovial fluids, and synovial biopsies of most RA patients, while osteoarthrosis, as a control, non-inflammatory population, showed no increased levels of this cytokine [25, 26] . Furthermore, emerging data show a body of evidence that IL-17 and Th17 cells may play a role in the pathogenesis of SLE and in lupus nephritis [27, 28] . Regarding an important systemic autoimmune disease, in patients with Sjögren's syndrome, IL-17 has been shown to play a pivotal role in the pathogenesis both in the peripheral blood and the cytokine that can be found with increased levels in the affected salivary glands [29, 30] .
It is interesting to speculate on what initiates and drives the shift in balance of the Th17 and regulatory T cells in autoimmune conditions. Regulatory T cells develop in the thymus and participate in the maintenance of peripheral tolerance. As we saw, in systemic autoimmune diseases, the circulating and local skewed cytokine milieu alters the suppressive function of these cells [31] . In affected organs, at the histological site of inflammation, a cytokine imbalance is present, with a predominance of IL-6 and TGF-β, which favor the development of Th17 cells. Th17 cells are pivotal in the initialization and progression of inflammatory processes, rather than Tregs; in addition, higher concentrations of tumor necrosis factor (TNF)-α downmodulates the function of Tregs [31] .
Since altered Th17 and regulatory T cell ratios may play a pathogenic role by tipping the fine balance toward enhanced immune reactivity, the disruption of this equilibrium has been studied in various systemic autoimmune conditions [32] [33] [34] [35] . In order to assess whether a shift in the cytokine homeostasis exists in autoimmune conditions, fueling the predominance of pro-inflammatory cells vs immunoregulatory T cells, we have measured a broad spectrum of circulating cytokines in patients with various systemic autoimmune and rheumatic diseases [36] [37] [38] [39] [40] [41] .
Cytokine Imbalance, Regulatory/Effector Cells in Various Well-defined Systemic Autoimmune and Rheumatic Diseases Primary Sjögren's Syndrome (pSS)
The Clinical Picture and Immunocompetent-cell Distribution of pSS Primary Sjögren's syndrome (pSS) is a chronic, slowly progressive, systemic autoimmune disease that predominantly affecting middle-aged women, although it can be seen in people of all ages, including children [42] . pSS is characterized by mononuclear infiltration and destruction of t h e e x o c r i n e g l a n d s , r e s u l t i n g i n d r y m o u t h , keratoconjunctivitis sicca, and the presence of other exocrinopathic symptoms, affecting various organs [42] . In the pathogenesis, a variety of native and adaptive cellular and humoral autoimmune processes have been described previously [42, 43] . On the adaptive immune system's side, different subsets of T and B lymphocytes and monocytes contribute to the pathogenesis. Increased cell activation, uncontrolled apoptotic processes, and immune response are partly driven by a skewed cytokine milieu contributing to the pathogenesis of the disease [43, 44] . Besides intra-glandular cytokines and chemokines, a group of peripheral cytokines, chemokines, and growth factors have been implicated in the pathogenesis of pSS, contributing to the perpetuation of the cellular and humoral autoimmune processes, leading to the pathognomonic clinical picture [44] [45] [46] [47] . In our previous study, we assessed how certain peripheral immune parameters reflect the inflammatory alterations in patients with pSS, determined lymphocyte subpopulations and their state of activation from peripheral blood, evaluating both soluble serum T helper (Th) 1/Th2-type cytokines, as well as intracytoplasmic cytokines [48] . We found that the skewed T cell subsets and cytokine imbalance play important roles in an orchestrated proinflammatory cascade. Patients with pSS were characterized by elevated percentages of activated T cells (CD3+/CD69+ T lymphocytes), compared to healthy individuals [48] . The assessment of naïve vs memory CD4+ and CD8+ T cells, we could identify a clear shift towards the memory phenotype in both T cell subsets. Th0 and Th1 cell numbers were increased in patients compared to controls. Concerning cells of the innate immune system, NK cell and NK T cell percentages were elevated in pSS patients.
Cytokine Imbalance in the Pathogenesis of pSS
In order to shed light, which cytokines might be responsible for the aforementioned cellular shifts, we measured serum cytokines in patients and healthy individuals in parallell. Interestingly, we found that among circulating cytokines, IFN-γ was high, whereas IL-10 was decreased in patients with pSS [48] . In addition, we and others have evaluated changes in regulatory cells and a wide spectrum of serum cytokine in pSS patients which seemed beneficial to cluster and subgroup patients with pSS [30, 41, [49] [50] [51] .
The great advantage of assessing various cytokines in patients with systemic autoimmune and rheumatic diseases is that the univariate and/or multivariate analyses of these cytokines aids to create and identify patient subsets in diseases, previously thought to be homogeneous. In line with this approach, we have previously showed that circulating cytokines have the ability to distinguish pSS patients with ectopic salivary gland germinal centers, a possible forerunner of lymphoma development in the disease [30, 41, 50] . In this study, univariate analysis demonstrated that serum levels of a broad spectrum of immune and inflammatory modulating cytokines are upregulated in both pSS patient groups (pSS patients with, or without ectopic germinal center formation), relative to unaffected controls: IL-1beta, IL-2, IL-6, IL-15, IFN-γ and CCL4 (MIP-1beta) [30] . pSS patients with ectopic germinal center formation were distinguished from healthy individuals by higher levels of IL-4, IL-10, GM-CSF, IFN-alpha, CCL3 (MIP-1alpha), CCL11 (eotaxin) and B cell activating factor (BAFF/BLyS), while germinal center positive and negative pSS patients differed in CCL2 (MCP-1) expression. Discriminant function analysis (DFA), a multivariate discrimination method that uses observed differences to characterize groups when casual relationships are not well understood, was employed to identify a subset of these biomarkers that maximally discriminate among germinal center positive and negative, as well as healthy individuals. The biomarker having the strongest discriminatory power identified by DFA were CCL11 (eotaxin), IFN-γ, as well as BAFF/BLyS [30] . These data indicate that the continuous monitoring of these biomarkers might aid in identifying the development of ectopic germinal center formation and presumably the subsequent development of lymphoma in patients with pSS.
Systemic Sclerosis
Systemic sclerosis (SSc) is a systemic disease of autoimmune pathogenesis, characterized by excessive extracellular matrix deposition and damage of the small blood vessels. SSc is associated with endothelial cell dysfunction, where classically, the microvasculature is affected. The hallmarks of the disease are inflammatory processes, dominantly in the skin and visceral organs, such as the heart, lungs, or kidneys [52, 53] . The key role of the innate and adaptive immune system has been depicted in the pathogenesis of SSc [54] [55] [56] [57] . Disorders of the immune system lead to chronic inflammatory processes, abnormal T cell activation, B cell abnormalities, abundant production of proinflammatory cytokines (e.g., IL-4) and the production of characteristic autoantibodies including anticentromere antibodies in limited SSc and anti-topoisomerase 1 and anti-RNA polymerase I/III antibodies in diffuse SSc.
Regulatory cells with impaired function have been shown to play a role in the initiation and perpetuation of the disease [56, 57] . In SSc patients, increased levels of circulating Th17 cell have been described, along with elevated IL-17 serum concentrations [58, 59] . On the helper T cell side, an altered balance of the Th1 and Th2 cytokine profile may also be responsible for the development of fibrosis [60] . Previously, we have depicted a wide spectrum of peripheral immunecompetent cell types, reflecting overall disturbances in immune homeostasis, characteristic of systemic sclerosis [61] . We found that patients with SSc had higher percentages of activated T cells, reflected by increased ratio of CD3+/HLADR+cells. Comparing naive vs memory subsets of CD4+ and CD8+ T cells, a shift towards central memory phenotype was observed. We saw an imbalance of various immunecompetent cell types of the innate immune system characterized by abnormal levels of NK and NKT cells.
Regulatory T Cells and the Cytokine Milieu in the Pathogenesis of SSc
We depicted a shift between the effector and regulatory T cell level in SSc. Increased Th-17 cell percentages, together with decreased levels of Th1, as well as regulatory T cell subsets, IL-10 producing Tr1 cells (CD4+IL-10+ T cells), and CD4+ CD25+FOXp3+ Treg cell were characteristic to these patients [61] . We also found decreased IL-10 levels in SSc. Besides the quantitative differences of regulatory cells between patients and controls, the functional assessment of Tregs identified that the suppressor activity of CD4+CD25+FOXP3+ Treg cells was clearly decreased in SSc, compared to healthy individuals. Our data suggest that the increased Th17/Treg ratio and the altered regulatory function of CD4+CD25+FOXP3+ Treg cells play an important role in the development and progression of SSc. Moreover, our study identified the potential role of the decreased presence of IL-10-producing Tr1 cells (along with lower IL-10 serum levels) in the progression of disproportionate immune responses in SSc [61] . Altogether, these findings suggest that the assessment of regulatory immune-competent cells and peripheral cytokines aids in the understanding the pathogenesis of these diseases, also serves as useful disease activity markers and helps to subcategorize autoimmune diseases. The Th17 cell and regulatory T cell imbalance, along with impaired circulating cytokine profile gives a good ground to use these parameters for therapy response assessment in SSc. Extracorporeal photochemotherapy (ECP) is a useful therapeutic modality in SSc; therefore, we enrolled patients with diffuse cutaneous SSc, whom received 12 ECP treatments in total and assessed various immunocompetent cell types, including regulatory cells and Th17 cells using intracellular cytokine staining [35] . We could see significant changes in these parameters following treatment. After a series of ECP, the percentages, and numbers of peripheral Th17 cells decreased, we observed a clear increase in Tr1 and Treg cell numbers, and interestingly, we could identify a functional improvement of Tregs, as reflected by the recovered suppressor capacity of Treg cells. Moreover, we found a positive correlation between the reduction of IL-17 levels and skin thickness, an objective measure of improvement in SSc. Concerning serum cytokines, chemokines, and growth factors, levels of CCL2 and TGF-beta decreased, while the concentration of IL-10, IL-1-receptor-alpha, and hepatocyte growth factor elevated during the therapy [35] . ECP had a clear effect on lymphocyte activation. We observed a significant negative correlation between the changes in peripheral activated CD95+ T cell and CD4+CD25+ Treg cell levels. We found negative correlations between CD69+ and HLA-DR+T cells and the functional ability of the CD4+CD25+ Treg cells following a series of ECP treatment. The initial increase of CD95+ expression in SSc reflects a state of lymphocyte activation during autoimmune processes, which can be effectively attenuated by the restoration of regulative T cell numbers and functions as the result of ECP therapy [62] . These results clearly indicate that the assessment of Th17 and regulatory T cell subsets along with soluble cytokines aids in the patient follow-up and therapy response monitoring in SSc
Mixed Connective Tissue Disease
Clinical Picture, Effector-and Regulatory-T Cell Profile of MCTD Patients In MCTD, the most frequently observed symptoms are arthritis, Raynaud's phenomenon, myositis, esophageal dysmotility, and acrosclerosis along with the presence of autoantibodies reactive with U1 small nuclear RNP (U1RNP) autoantigens [63] [64] [65] . Long-term follow-up studies reveal that other symptoms, such as serositis (pleuritis, pericarditis), pulmonary involvement, skin involvement, neuropsychiatric disease, and glomerulonephritis, may also develop in this systemic autoimmune disease [66] [67] [68] [69] [70] . Previously, we assessed serum cytokines and intracellular cytokine production of CD4+ and CD8+ T cells in patients with MCTD [71] . Serum concentrations of both type 1 and type 2 cytokines were significantly higher in patients with MCTD than in healthy controls. In patients with active MCTD, the percentage of CD8+/IFN-γ+, cytotoxic type-1 T lymphocytes was significantly increased compared to its level in inactive disease or healthy individuals. IL-4 expression of CD4+ T cells (representing Th2 cells) was scarcely detectable in MCTD. A higher percentage of CD8+/IL-4+, cytotoxic type 2 T cells were detected in patients, especially in those with active disease, compared to controls. The percentage of IL-10-producing CD4+ and CD8+ T cells was higher in patients than in controls. Again, CD4+ and CD8+ T cells from patients with active MCTD produced significantly more IL-10 than cells in patients with inactive disease or in healthy individuals [71] . These findings support the idea that MCTD is characterized by a wide spectrum of T cell abnormalities, which becomes explicit in the active phase of the disease. Concerning the role of immunoregulatory abnormalities in the pathogenesis, we assessed CD4+CD25+ regulatory T cells in patients with MCTD. In line with findings from patients with other systemic autoimmune, rheumatic diseases, the percentage and the absolute number of CD4+CD25+high Treg cells were lower in patients than in healthy controls which further decreased in patients with active disease. Interestingly, we saw an increase in the percentage and absolute number of CD4+IL-10+ Tr1 cells in patients with MCTD compared to healthy controls. The percentage of Tr1 cells was higher in the active stage of MCTD than in the inactive stage. The decrease in the number of CD4+CD25+high Treg cells in an important factor in the immunoregulatory disturbance in patients with MCTD. We believe that elevated Tr1 cell percentages could be a compensatory mechanism aiming to restore the balance between type 1 and type 2 cytokines in MCTD [72] .
Characterisation of Serum Cytokines and Regulatory Cells in MCTD
As we discussed previously, the assessment of regulatory cells and serum cytokine monitoring can be a useful tool in disease subcategorization. In order to depict the value of cytokine measurement and regulatory cell assessment in MCTD, we investigate the frequency of sensorineural hearing loss (SNHL) in patients with MCTD and evaluated various immunological parameters in patients with or without this inner ear disorder. Serum levels of IFN-γ and TNF-alpha were increased in MCTD patients with SNHL compared to patients without SNHL. The absolute number of Tregs was lower compared to patients without SNHL. The decreased levels of regulatory T cells, along with the increased expression of pro-inflammatory cytokines may play a role in the pathogenesis of immune-mediated inner ear disorders in MCTD [73] .
In another approach, in order to use cytokine assessment in disease profiling, we evaluated the vitamin D status in MCTD patients and assessed which clinical symptoms, laboratory parameters, and endothelial cell markers are associated with low vitamin D levels. We found that vitamin D levels were inversely associated with serum IL-6, IL-23, and IL-10 cytokine levels, while low vitamin D levels were also significantly associated with carotid artery intima media thickness, fibrinogen, total cholesterol, and ApoA1 levels. The presence of cardiovascular diseases showed an inverse correlation with vitamin D status in MCTD. By assessing peripheral cytokines in MCTD, we could identify that vitamin D insufficiency along with inflammatory parameters, reflected by increased serum pro-inflammatory cytokine levels, may provoke cardiovascular events [74] . Serum and intracellular cytokine assessment, reflecting immune-regulatory abnormalities are valuable biomarkers to assess disease activity in MCTD, also capable of subcategorizing these patients, as well.
Systemic Lupus Erythematosus (SLE)
Clinical Picture and Pathogenesis SLE is a heterogeneous, multietiological systemic autoimmune disease with various organ involvements, encompassing mild to moderate forms, and also severe, progressive variants [75] [76] [77] . The organ manifestations of the disease include dermatologic signs, arthritis, and serositis, as well as renal, neurologic, and hematologic disorders. Serologically, lupus is characterized by the presence of antinuclear antibodies (80-90 % of patients), double-stranded DNA-directed autoantibodies (58-70 % of patients), and antibodies directed to other nuclear antigens, such as histones and small nuclear ribonucleoproteins (snRNP) in a minor group of patients.
Cytokines and Immune-regulatory Defects
Several cytokines have also been implicated in the pathogenesis of SLE, amongst others BAFF/BLyS, TNF-α, IFN-α, IFN-γ, IL-12, IL-23, IL-18, IL-6, IL-10 and IL-17 forming a rationale also for therapeutic intervention in the disease [78, 79] .
Previous studies on gene polymorphisms in SLE risk genes identified the key roles of particular cytokines in the pathogenesis. Thus, an SLE risk haplotype of interferon regulatory factor-5 (IRF5) has been shown to be linked to the increased production of IFN-α, and an autoimmune disease risk variant of signal transducer and activator of transcription 4 (STAT4) causes increased sensitivity to IFN-α in patients with SLE [80, 81] . The protein, encoded by TNF-induced protein 3 gene (TNFAIP3), on the other hand, inhibits nuclear factor κB-dependent signaling and, thus, prevents inflammation that is caused by multiple cytokines [82] . Genetic variation, therefore, could help to explain the increases in a wide range of cytokine responses in SLE. Recently, an interesting study evaluated changes in plasma concentrations of soluble mediators preceding clinically defined disease flares in SLE. They found that patients with impending flare had significant alterations in a wide variety of soluble mediators at baseline with significantly higher levels of pro-inflammatory mediators, including Th1, Th2, and Th17-type cytokines, several weeks before clinical flare compared to clinically stable patients [83] . Levels of regulatory cytokines, including IL-10 and TGF-β were higher in non-flare SLE patients, while baseline levels of soluble TNFRI, TNFRII, Fas, FasL, and CD40L were significantly greater in pre-flare patients. These findings support the idea that alterations in the balance between inflammatory and regulatory mediators may help identify patients at risk of disease flare and help decipher SLE pathogenic mechanisms [83] . Concerning the role of regulatory T cells in SLE, most studies point to a reduction in Treg cell number and function in SLE [84] [85] [86] . The role of Th17 cells has been described in the pathogenesis of SLE, and several studies have reported an increase in Th17 cells and IL17 in SLE and in particular with disease flare [87] [88] [89] . The Th17 and Treg ratio indicates that SLE is associated with a reduction in the levels and function of immunosuppressive Treg cells together with an increase in the pro-inflammatory Th17 cells [90] . Table 1 summarizes the relevant findings in cytokine imbalance and regulatory/ effector cell makeup in UCTD and systemic autoimmune diseases.
In UCTD, the Th17/Treg Ratio Signifies Progression Toward Well-defined Systemic Autoimmune Diseases
As we have illustrated, in all these various patient groups with systemic autoimmune conditions, we could identify a circulating cytokine imbalance, clearly reflecting a proinflammatory milieu; moreover, this particular cytokine imbalance and skewed pattern had the ability to promote the development of Th17 cells and the reduction in numbers/ function of Tregs. UCTD is a very unique clinical entity, representing the initial stages of systemic autoimmune diseases. UCTD patients can have various clinical symptoms, s p e c i f i c f o r a u t o i m m u n e d i s e a s e s , a l o n g w i t h immunoserological abnormalities; yet, they do not meet the standard criteria for any well-defined systemic autoimmune disease [42] [43] [44] [45] . The clinical symptoms and the presence of the autoantibodies in UCTD suggest that many of the same immunological abnormalities that play a role in different welldefined systemic autoimmune diseases can also be involved in UCTD. Taken together, these findings point to that the Th17/ Treg imbalance can be a good marker of a subsequent transition of these patients toward well-defined systemic autoimmune diseases. Accordingly, we have assessed Th17 cells, as well as regulatory T cell subsets in patients with UCTD, and identified whether the imbalance of these immunologically important cell types contribute to the development of a subsequent definitive systemic autoimmune and rheumatic diseases [46] . In this study, we found that the most common clinical manifestations of these UCTD patients were polyarthritis, Raynaud's phenomenon, and various skin symptoms, amongst others photosensitivity, malar rash and sclerodactily. Immunoserological abnormalities included positive ANA, ENA, RF, aSSA most frequently. The patients were followed up for 5 years and changes of clinical activity, serological abnormalities, as well as the Th17 and Treg subsets were registered consecutively [46] . Th17 cells were found to be increased in UCTD patients, when compared to healthy individuals. Moreover, Th17 cells were further increased in UCTD patients that subsequentially developed systemic autoimmune/rheumatic disease. Interestingly, the Th17/Treg ratio gradually increased from controls through UCTD patients, reaching the highest values in those, whom eventually progressed into definitive systemic autoimmune Since previous findings in systemic autoimmune and rheumatic diseases indicated a skewed cytokine milieu which could fuel the shift of the Th17/Treg balance, we have assessed a variety of circulating cytokines in patients with UCTD and found that the levels of IL-6, IL-12, IL-17, IL-23, and IFN-γ were pathologically increased with a parallel reduced level of IL-10, which imbalance was normalized after alfacalcidiol treatment [47, 48] . In parallel with the proinflammatory cytokine imbalance, increased Th17 with reduced Treg cell counts with a high Th17/Treg ratio was observed, which could be reverted by administering vitamin D to these patients [47, 48] . These findings indicate that at a very early stage of systemic autoimmune disease development, a shift of a cytokine imbalance, favoring a proinflammatory milieu, is present, contributing to a biased Th17/Treg distribution, which further initiates and perpetuates tissue damage and the development of the disease-specific clinical symptoms. Presumably, this functions as a reverberating cycle, as the tissue damage increases further shift in the cytokine balance and a consequent regulatory/effector T cell disequilibrium. Taken these findings together, it seems that the simultaneous, opposing effect of Th17 cells and Tregs has a strong impact on immune homeostasis, deciding and controlling the development of autoimmunity in these patients. Figure 1 summarizes the pathways and interconnections between tissue damage, skewed cytokine milieu, and their role in the development of regulatory T cell and Th17 cell imbalance in autoimmune conditions.
Concluding Remarks
Finally, we should emphasize that besides the background Th17/Treg imbalance and cytokine dysequilibrium, a diverse antibody repertoire is present and may drive the development of various organ symptoms, leading to various autoimmune diseases. What determines the type of antibody produced and the type of systemic autoimmune disease developed? Why does the process stop for many patients at the UCTD stage without further progression? We believe that immuneregulatory responses should be followed in patients closely in the UCTD stage, and presumably if only temporary or mild dysfunction can be seen in this machinery, that may not cause severe organ damage. To answer these questions is obviously a huge task, in which knowledge of genetics, regulatory cell functions, Th17 cell development, and assessment of the cytokine milieu should be involved.
Our findings support the idea that the pathological immuno-regulatory balance between Th17 cells and T cells with regulatory capacity at least partly drives the development of UCTD and its progression to definitive systemic autoimmune, rheumatic diseases. Therefore, the assessment of these parameters in patients with UCTD may be a useful marker to identify high-risk individuals with a potential for disease progression. We believe that the disruption of this vicious cycle at a very early stage of the disease development (early UCTD stage) by the administration of immunomodulating agents (e.g., alfacalcidiol, vitamin D derivates) can modulate the clinical picture, modify, and decelerate the progression toward full-blown systemic autoimmune/rheumatic diseases.
